As GLP-1 weight loss medications continue to surge in popularity, NFL legend Tom Brady is getting in on the action, using his wellness brand to “democratize” the health care system in a way the world has “never seen.”
The seven-time Super Bowl champion has teamed up with eMed, a digital health company managing sustainable ways to offer GLP-1 drugs while helping employers reduce health insurance claims.
“There’s an epidemic in America, the disease of obesity, and how can we democratize health and wellness in a way that the world has never seen?” Brady said in an exclusive interview with “The Claman Countdown” Wednesday.
DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTH
Serving as eMed’s chief wellness officer, Brady hopes to help people live better, healthier lives by harnessing the power of weight loss medications, lamenting America’s obesity epidemic.
“I love seeing people live a better life, live a healthier life, feel better, do the things that they want to do in the end. It’s always been a struggle in our country,” the football legend said.
“There’s no debate about the way that this medicine is working right now in terms of keeping people and getting people on their wellness journey started.”
TOM BRADY LAUNCHES GOOD NUT COCONUT WATER LINE WITH GOPUFF IN MARKET EXPECTED TO REACH $11B BY 2030
EMed CEO Linda Yaccarino previously said the goal is to apply Brady’s “rigor” to improve the health of the American workforce and minimize chronic diseases.
With more than 60% of Americans receiving health benefits through an employer, eMed aims to incentivize companies to cover GLP-1 medications for eligible workers, Yaccarino said.
“We do a great job of saving employers’ money and getting people healthy,” Brady said.
AMERICANS ARE GIVING UP MULTIVITAMINS FOR A DIFFERENT DAILY HEALTH HABIT, STUDY FINDS
“There’s finally, for the first time, a health benefit, attacking all these chronic diseases and a financial benefit to employers. So, it’s giving them incentive to cover the medications,” Yaccarino added.
Yaccarino described GLP-1 medications as the “pharmaceutical revolution” of the modern age while outlining the support eMed provides to patients.
“Once we bring our members onto our program, we combine AI, technology and continuous clinical support so they stay with us,” she said.
